Regeneron Pharmaceuticals, Inc. $REGN Stock Acquired by Factory Mutual Insurance Co.

Key Points

• Factory Mutual Insurance Co. increased its Regeneron stake by 11.1% in the third quarter, adding 2,832 shares to reach 28,232 shares valued at about $21.4 million.
• Regeneron’s latest quarterly results beat estimates: earnings were $20.07 per share versus $16.51 expected, and revenue reached $5.12 billion, up 36.3% year over year.
• Analyst sentiment is broadly positive, with a MarketBeat average rating of “Moderate Buy” and an average price target of $898.97, though some firms have expressed valuation caution after the stock’s rally.

Factory Mutual Insurance Co. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,232 shares of the biopharmaceutical company's stock after buying an additional 2,832 shares during the quarter. Factory Mutual Insurance Co.'s holdings in Regeneron Pharmaceuticals were worth $21,407,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Eads & Heald Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 54.8% during the third quarter. Eads & Heald Wealth Management now owns 534 shares of the biopharmaceutical company's stock worth $405,000 after purchasing an additional 189 shares in the last quarter. Trek Financial LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $221,000. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Regeneron Pharmaceuticals by 165.2% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,904 shares of the biopharmaceutical company's stock valued at $1,433,000 after purchasing an additional 1,186 shares during the last quarter. Columbia Bank increased its holdings in shares of Regeneron Pharmaceuticals by 12.9% in the third quarter. Columbia Bank now owns 2,563 shares of the biopharmaceutical company's stock valued at $1,943,000 after purchasing an additional 292 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $95,976,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ:REGN opened at $973.36 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $591.52 and a one year high of $975.49. The company has a 50 day moving average of $798.74 and a 200-day moving average of $740.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. The stock has a market cap of $100.22 billion, a price-to-earnings ratio of 20.13, a P/E/G ratio of 1.51 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same period in the prior year, the business posted $11.83 earnings per share. Regeneron Pharmaceuticals's revenue was up 36.3% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.30%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the company's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $900.00, for a total value of $360,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at approximately $542,700. This trade represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,493 shares of company stock worth $6,866,845. 6.97% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on REGN. Weiss Ratings upgraded shares of Regeneron Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research report on Monday. Canaccord Genuity Group increased their price objective on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a "buy" rating in a research report on Wednesday, October 28th. Bank of America lifted their target price on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a "buy" rating in a research note on Monday. Piper Sandler boosted their target price on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an "overweight" rating in a research report on Monday, October 19th. Finally, Raymond James Financial boosted their target price on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $898.97.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported third-quarter revenue of $5.12 billion, up 36.3% year over year and ahead of estimates, while earnings of $20.07 per share also topped consensus. Analysts pointed to strength in commercial products and progress in the pipeline as signs of underlying business health. REGN Q3 deep dive: pipeline progress and core brands drive outperformance
• Positive Sentiment: Following the results, multiple firms raised their price targets; some maintained Buy or Overweight ratings, and forecasts cited in coverage reached as high as $1,175. These revisions reflect improved expectations after the earnings beat. Analysts raise forecasts after upbeat Q3 results
• Neutral Sentiment: Director Kathryn Guarini sold 400 shares under a pre-arranged Rule 10b5-1 trading plan. The planned nature of the sale may reduce its significance as a signal about the company’s outlook. SEC filing
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, with a 0.4% indicated yield. Management also scheduled appearances at upcoming healthcare investor conferences; neither announcement provides a major near-term earnings catalyst. Investor conference presentations
• Negative Sentiment: Despite raising targets, several firms—including RBC, Morgan Stanley, Bernstein and Wells Fargo—kept neutral-style ratings and set targets below the recent share price, signaling valuation caution after the stock’s rally. RBC comments on Regeneron’s Q3 results

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.